Aurobindo Pharma Limited has officially announced the re-appointment of M/s. Ernst & Young LLP to serve as the company’s internal auditor. The engagement, confirmed by the Board of Directors on May 21, 2026, will span a duration of one year, covering the period from June 2026 to May 2027. This move ensures continued focus on robust risk management and governance standards for the organization.
Continuity in Governance and Risk Management
Following a recent meeting held on May 21, 2026, the Board of Directors of Aurobindo Pharma Limited approved the continued engagement of Ernst & Young LLP (EY). By retaining EY, the company aims to maintain its commitment to stringent risk management, internal control, and corporate governance frameworks.
Scope of Engagement
The re-appointment covers the fiscal year extending from June 2026 through May 2027. EY will continue to provide internal audit services, leveraging their extensive expertise in process improvement, technology integration, and regulatory compliance. Their role is pivotal in addressing unique organizational challenges and providing actionable insights that support informed decision-making and sustainable long-term growth.
Strategic Focus
The ongoing partnership with EY will focus on enhancing the company’s internal audit methodologies. By combining deep industry knowledge with innovative audit solutions, the firm will continue to monitor the company’s operational processes, ensuring that stakeholders receive valuable assurance regarding the integrity of the firm’s internal controls and management systems.
Source: BSE
